12.1 Oncology PET/CT Imaging with F-18 FDG

12.1 Oncology PET/CT Imaging with F-18 FDG

Quick Answer: F-18 Fluorodeoxyglucose (FDG) is a radiolabeled glucose analog used extensively in Positron Emission Tomography (PET) to evaluate the metabolic activity of tissues. By taking advantage of the Warburg effect—where cancer cells rely heavily on glycolysis—FDG can identify primary malignancies, metastatic spread, and tumor recurrence. Precise patient preparation and quantitative measures like the Standardized Uptake Value (SUV) are required for accurate interpretation.

1. The Physiological Basis of F-18 FDG

The application of F-18 FDG in oncology is fundamentally based on differences in cellular metabolism between normal and neoplastic tissues.

The Warburg Effect

Normal cells typically generate energy (ATP) through oxidative phosphorylation in the mitochondria in the presence of oxygen. In contrast, many cancer cells rely heavily on aerobic glycolysis—a phenomenon known as the Warburg effect. Even when oxygen is plentiful, these rapidly dividing tumor cells process glucose inefficiently through glycolysis, necessitating a massive increase in glucose uptake to meet their energy demands. F-18 FDG, acting as a glucose analog, is taken up by these cells in large quantities.

Transport and Metabolic Trapping

F-18 FDG is transported across the cell membrane by the same glucose transporter proteins (such as GLUT-1 and GLUT-3) that facilitate normal glucose transport. Once inside the cytoplasm, the enzyme hexokinase phosphorylates F-18 FDG to create F-18 FDG-6-phosphate.

In a normal glycolytic pathway, glucose-6-phosphate would proceed to the next enzymatic step. However, the molecular structure of FDG prevents it from being further metabolized by phosphohexose isomerase. Furthermore, because most cancer cells lack the enzyme glucose-6-phosphatase (which could dephosphorylate the molecule and allow it to exit the cell), the F-18 FDG-6-phosphate becomes irreversibly trapped inside the tumor cell. This process, termed metabolic trapping, allows the radiotracer to accumulate over time, creating a high target-to-background ratio that is visible on PET imaging.

2. Patient Preparation Protocols

Proper patient preparation is perhaps the most critical aspect of a successful F-18 FDG PET/CT scan. Deviations from these protocols can result in altered biodistribution, degraded image quality, and diagnostic errors.

Dietary and Fasting Requirements

• Fasting: Patients are required to fast (NPO) for at least 4 to 6 hours prior to the radiotracer injection. This fasting period is necessary to lower endogenous blood glucose and insulin levels.
• Insulin and Blood Glucose: High insulin levels drive FDG into skeletal muscle and the myocardium, creating intense background activity that can obscure lesions. Furthermore, high blood glucose competitively inhibits FDG uptake into tumor cells. Therefore, blood glucose levels must be checked before injection; ideally, levels should be < 150 mg/dL, and they strictly must be < 200 mg/dL. If the level exceeds the threshold, the scan may need to be rescheduled.

Hydration and Medications

• Hydration: Patients should drink plain water (no sugars or flavorings) before and after the injection. Adequate hydration promotes diuresis, which helps clear unbound FDG from the soft tissues and blood pool through the kidneys, reducing background radiation and the radiation dose to the bladder wall.
• Medications: Diabetic patients require specific scheduling. Typically, short-acting insulin should not be administered within 2 to 4 hours of the FDG injection.

Environmental Control and Activity

• Resting State: After the injection, patients must rest quietly in a dimly lit, comfortable room for the duration of the uptake phase (usually 60 minutes). They should avoid talking, chewing gum, reading, or using smartphones. Any muscle activity will lead to physiological FDG uptake in the activated skeletal muscles (e.g., vocal cords, masseters, ocular muscles), which can mask pathology.
• Temperature Control: The resting room must be kept warm. Exposure to cold causes the activation of brown adipose tissue (BAT), which utilizes glucose to generate body heat. BAT uptake often appears symmetrically in the supraclavicular, cervical, and paravertebral regions, mimicking lymph node metastases.

3. Standardized Uptake Value (SUV)

The Standardized Uptake Value (SUV) is a fundamental semi-quantitative metric used in PET imaging to measure the relative concentration of radiotracer in a specific lesion. It provides an objective way to compare metabolic activity over time, such as assessing the response to chemotherapy.

SUV Calculation

The basic formula for SUV normalizes the measured tissue activity by the injected dose and the patient's body weight:

SUV = (Tissue Activity Concentration in mCi/g) / (Injected Dose in mCi / Patient Body Weight in g)

An SUV of 1.0 represents a uniform distribution of the radiotracer throughout the entire body. Malignant tumors often exhibit SUVs significantly greater than 2.5 or 3.0, though this is not a strict cutoff.

Factors Influencing SUV

Several variables can alter the calculated SUV, making standardization crucial:

1. Uptake Time: FDG accumulation is a dynamic process. The time between injection and scanning must be strictly controlled (typically 60 minutes). If a follow-up scan is performed at 90 minutes instead of 60, the SUV cannot be accurately compared.
2. Body Composition: Because FDG does not distribute well into fat, obese patients may have artificially elevated SUVs in non-fat tissues when normalized to total body weight. Adjusting the formula to use Lean Body Mass (SUV_lbm) or Body Surface Area (SUV_bsa) provides a more accurate assessment.
3. Dose Infiltration: If the radiotracer is partially extravasated during intravenous injection, the actual circulating dose is lower than the assumed injected dose. This results in an artificially low calculated SUV.
4. Partial Volume Effect: The spatial resolution of a standard PET/CT scanner is approximately 4-5 mm. For lesions smaller than 1 to 2 cm, the measured activity concentration will be averaged with surrounding background tissue, leading to an underestimation of the true SUV.
5. Blood Glucose Level: Higher circulating glucose levels will competitively inhibit FDG uptake, lowering the SUV.

4. Normal Biodistribution vs. Pathological Uptake

Interpreting an FDG PET/CT requires a solid understanding of where the radiotracer normally accumulates.

Physiological Uptake

• Brain: The cerebral cortex relies almost exclusively on glucose for metabolism, resulting in intense, symmetric uptake.
• Myocardium: Cardiac uptake is highly variable and depends on the patient's fasting state. In a fasting state, the heart typically switches to fatty acid metabolism, reducing FDG uptake. However, some residual or intense focal uptake can still occur normally.
• Urinary Tract: F-18 FDG is not reabsorbed by the renal tubules. It is rapidly excreted in the urine, causing intense activity in the kidneys, ureters, and urinary bladder.
• Liver and Spleen: These organs typically demonstrate mild to moderate, uniform uptake. The liver is often used as a background reference organ.
• Gastrointestinal Tract: Variable uptake is frequently seen in the stomach, small bowel, and colon due to smooth muscle activity and intraluminal bacteria.
• Lymphoid Tissue: The tonsils and salivary glands often show mild symmetric uptake.

Pathological Uptake

Pathological FDG uptake is typically focal, asymmetrical, and more intense than the surrounding background tissue.

• Malignancies: Primary tumors (e.g., non-small cell lung cancer, colorectal cancer, melanoma, lymphoma) and their metastases typically show intense avidity due to the Warburg effect.
• Inflammation and Infection: It is crucial to remember that FDG is not tumor-specific. Activated inflammatory cells, such as macrophages and neutrophils, also rely heavily on glycolysis. Conditions like pneumonia, active sarcoidosis, tuberculosis, surgical incisions, and localized infections will demonstrate intense FDG uptake, serving as a primary source of false-positive oncology scans.

5. Summary of Oncological Imaging

F-18 FDG PET/CT is primarily utilized for diagnosis, staging, restaging, and treatment monitoring, taking advantage of the increased metabolic activity of cancer cells.